Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 5, 2000, Pages 1186-1194

  Maga, Giovanni ^a   Ubiali, Daniela ^a   Salvetti, Raul ^a   Pregnolato, Massimo ^a,b   Spadari, Silvio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b Dipartimento di Chimica Generale   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; RNA DIRECTED DNA POLYMERASE INHIBITOR; SEFAVIRENZ; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL;

ANTI-HIV AGENTS; BINDING, COMPETITIVE; CATALYTIC DOMAIN; DRUG SYNERGISM; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; KINETICS; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; THYMINE NUCLEOTIDES; ZIDOVUDINE;

EID: 0034094279     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.5.1186-1194.2000     Document Type: Article

References (33)

1. Adkins, J. C., and S. Noble. 1998. Efavirenz. Drugs 56:1055-1066.
2. Barnard, J., G. Borkow, and M. Parniak. 1997. The chiocarboxanilide non-nucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase. Biochemistry 36:7786-7792.
3. Debyser, Z., A.-M. Vandamme, R. Pauwels, M. Baba, J. Desmyter, and E. D. Clercq. 1992. Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2′,3′-dideoxynucleoside 5′-triphosphale, tetrahydroimidazo[4,5,1-jk]-[1,4]-benzodiazepin-2-(1H)-thione and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives. J. Biol. Chem. 267: 11769-11776.
4. De Clercq, E. 1999. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Farmaco 54:26-45.
5. De Clercq, E. 1993. HIV-1-specific reverse transcriptase inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase. Med. Res. Rev. 13:229-258.
6. Dixon, M., and E. C. Webb. 1979. Enzymes. Longman. London, England.
7. Esnouf, R., J. Ren, C. Ross, Y. Jones, D. Stammers, and D. Stuart. 1995. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat. Struct. Biol. 2:303-308.
8. Fletcher, R. S., K. Syed, S. Mithani, G. I. Dimitrienko, and M. A. Parniak. 1995. Carboxanilide derivative non-nucleoside inhibitors of HIV-1 reverse transcriptase interact with different mechanistic forms of the enzyme. Biochemistry 34:4346-4353.
9. Graul, A., J. Rabasseda, and J. Castañer. 1998 Efavirenz. Drugs Future 23:133-141.
10. Greco, W. R., G. Bravo, and J. C. Parsons. 1995. The search for synergy: a critical review from a response surface perspective. Pharm. Rev. 47:331-385.
11. Hottiger, M., and U. Hübscher. 1996. Human immunodeficiency virus type 1 reverse transcriptase. Biol. Chem. Hoppe-Seyler 377:97-120.
12. Hsieh, J.-C., S. Zinnen, and P. Modrich. 1993. Kinetic mechanism of the DNA-dependent DNA polymerase activity of human immunodeficiency virus reverse transcriptase. J. Biol. Chem. 268:24607-24613.
13. Hsiou, Y., J. Ding, K. Das, A. D. Clark, Jr., S. H. Hughes, and E. Arnold. 1996. Structure of unliganded HIV-1 reverse transcriptase at 2.7 Å resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure 4:853-860.
14. Huang, H., R. Chopra, G. L. Verdine, and S. C. Harrison. 1998. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282:1669-1672.
15. Hübscher, U., and S. Spadari. 1994. DNA replication and chemotherapy. Physiol. Rev. 74:259-304.
16. Joergensen, K. A., A. B. Ghattas, and S. O. Lawesson. 1982. The =C=S → =C=O transformation using the soft NO(+)-species. Tetrahedron 38: 1163-1168.
17. Kali, W. M., K. A. Johnson, L. F. Jerva, and K. S. Anderson. 1992. Mechanism and fidelity of HIV reverse transcriptase. J. Biol. Chem. 267:25988-25997.
18. Kohlstaedt, L. A., J. Wang, J. M. Friedman, P. A. Rice, and T. A. Steitz. 1992. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
19. Larder, B. A. 1994. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J. Gen. Virol. 75:951-957.
20. Maga, G., M. Amacker, N. Ruel, U. Hübscher, and S. Spadari. 1997. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. J. Mol. Biol. 274:738-747.
21. Mellors, J. W., G. E. Dutschman, G. J. Im, E. Tramontano, S. R. Winkler, and Y. C. Cheng. 1992. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mol. Pharmacol. 41:446-451.
22. Oxford, J. S., A. A. Al-Jabri, C. A. Stein, and P. Levantis. 1996. Analysis of resistance mutants of viral polymerases. Methods Enzymol. 275:555-601.
23. Reardon, J. E. 1993. Human immunodeficiency virus reverse transcriptase: a kinetic analysis of RNA-dependent and DNA-dependent DNA polymerization. J. Biol. Chem. 268:8743-8751.
24. Reardon, J. E. 1992. Human immunodeficiency virus reverse transcriptase: steady-state and pre-steady-state kinetics of nucleotide incorporation. Biochemistry 31:4473-4479.
25. Ren, J., R. Esnouf, E. Garman, D. Somers, C. Ross, I. Kirby, J. Keeling, G. Darby, Y. Jones, D. Stuart, and D. Stammers. 1995. High resolution structures of HIV-1 RT from four RT- inhibitor complexes. Nat. Struct. Biol. 2:293-302.
26. Richman, D., C. K. Shih, I. Lowy, P. Prodanovich, S. Goff, and J. Griffin. 1991. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. USA 88:11241-11245.
27. Richman, D. D., D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S. A. Spector, J. Sullivan, S. Cheeseman, K. Barringer, D. Pauletti, C.-K. Shih, M. Myers, and J. Griffin. 1994. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1660-1666.
28. Spence, R. A., W. M. Kati, K. S. Anderson, and K. A. Johnson. 1995. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267:988-993.
29. Tan, L., C.-Y. Chen, R. D. Tyller, E. J. J. Grabowski, and P. J. Reider. 1999. A novel, highly enantioselective ketone alkynylation reaction mediated by chiral zinc aminoalkoxides. Angew. Chem. Int. Ed. Engl. 38:711-713.
30. Tantillo, C., J. Ding, A. Jacobo-Molina, R. G. Nanni, P. L. Boyer, S. H. Hughes, R. Pauwels, K. Andries, P. A. Janssen, and E. Arnold. 1994. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. J. Mol. Biol. 243:369-387.
31. Villahermosa, M. L., J. J. Martinez-Irujo, F. Cabodevilla, and E. Santiago. 1997. Synergistic inhibition of HIV-1 reverse transcriptase by combinations of chain-terminating nucleotides. Biochemistry 36:13223-13231.
32. Young, S. D., S. F. Britcher, L. O. Tran, L. S. Payne, W. C. Lumma, T. A. Lyle, J. R. Huff, P. A. Anderson, D. B. Olsen, S. S. Carroll, D. J. Pettibone, J. A. O'Brien, R. G. Ball, S. K. Balani, J. H. Lin, I.-W. Chen, W. A. Schleif, V. V. Sardana, W. J. Long, V. W. Byrnes, and E. A. Emini. 1995. L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 39:2602-2605.
33. Young, S. D., L. S. Payne, S. F. Britcher, L. O. Tran, and W. C. J. Lumma. September 1997. Benzoxazinones as inhibitors of HIV reverse transcriptase. Merck & Co., Inc. U.S. patent 5,663,169.